SCHEMBL718339

SCHEMBL718339

Cc1ccc(NC(=O)C2(C)CCCCC2)cc1Cc1nc(-c2cccnc2)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.44
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
NPC1 O15118 5/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
ABL1 P00519 5/20 0.42
BCR P11274 5/20 0.42
PDGFRB P09619 3/20 0.42
PDGFRA P16234 2/20 0.42
EGFR P00533 1/20 0.42
ERBB2 P04626 1/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
CSF1R P07333 1/20 0.42
YES1 P07947 1/20 0.42
LYN P07948 1/20 0.42
HCK P08631 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716174 0.83 KDM4E (0.54) RAB9AKMT2AMEN1NPC1CASP3
SCHEMBL10082809 0.82 GAA (0.61) RAB9AKMT2AMEN1NPC1CASP3
SCHEMBL716307 0.80 KDM4E (0.52) RAB9AKMT2AMEN1NPC1CASP3
SCHEMBL714837 0.77 NPC1 (0.53) RAB9AKMT2AMEN1NPC1CASP3
SCHEMBL5503213 0.77 ABL1 (0.51) ABL1BCRPDGFRBPDGFRAEGFR
SCHEMBL5159104 0.77 DYRK1A (0.45) RAB9AKMT2AMEN1NPC1CASP3
SCHEMBL5162199 0.77 ABL1 (0.64) ABL1BCRPDGFRBPDGFRAEGFR
SCHEMBL720659 0.77 ABL1 (0.59) RAB9AKMT2AMEN1NPC1ABL1
SCHEMBL718546 0.76 ABL1 (0.49) ABL1BCRPDGFRBPDGFRAEGFR
SCHEMBL4902752 0.76 ALDH1A1 (0.54) RAB9AKMT2AMEN1NPC1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053186-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2012-03-01 US disclosed
US-20110201620-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053186-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS KIT, CHUK, MAP3K2 RAB9A 1947/4885KMT2A 381/4885MEN1 3487/4885
US-20110201620-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS KIT, ABL1, MUSK RAB9A 599/4885KMT2A 167/4885MEN1 696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.